We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Causal Role Found for Common Genetic Variant in Narcolepsy

By LabMedica International staff writers
Posted on 14 Jan 2014
Image: Structure of the major histocompatibility complex, class II, DQ beta 1 (HLADQB1) gene (Photo courtesy of Protein Data Bank).
Image: Structure of the major histocompatibility complex, class II, DQ beta 1 (HLADQB1) gene (Photo courtesy of Protein Data Bank).
An extraordinary association has been found between a specific gene variant related to the human leukocyte antigen immune system and narcolepsy.

Narcolepsy may be caused by an autoimmune response to an environmental trigger such as an infection and in people who are genetically susceptible to narcolepsy, the immune system may respond to the trigger by mistakenly attacking and destroying brain cells that make hypocretin, a hormone that helps promote alertness.

A large team of European scientists led by those at the University of Lausanne (Switzerland) performed a modified genome-wide association study involved 1,261 people with narcolepsy. This represented nearly 90% of European patients suffering from narcolepsy with cataplexy who have complete diagnostic work-up and DNA available. They were matched with 1,422 controls. High-resolution genotyping identified genetic variants including those in the human leukocyte antigen (HLA) system, which contains genes related to immune system function. Analysis was performed by logistic regression.

The investigators found that participants with the major histocompatibility complex, class II, DQ beta 1 (HLA-DQB1) allele DQB1*06:02 were 251 times more likely to have narcolepsy with cataplexy than participants without the gene variant. This gene variant had a remarkably high negative predictive value of 99.32%, which means that nearly 100% of narcolepsy with cataplexy patients are DQB1*06:02 positive. Four other DQB1 alleles provided protection against narcolepsy, strongly supporting a causal role for DQB1 in narcolepsy. They suggested that high-resolution genotyping could play a valuable role in diagnosing patients suspected of having narcolepsy and evaluating at-risk populations.

Mehdi Tafti, PhD, the lead author and a professor in the Center for Integrative Genomics, said, “For the first time we have tested the HLA association all over Europe. This almost 100% association with HLA is somehow unique to narcolepsy and suggests a causal implication.” People with narcolepsy experience repeated daily episodes of an irrepressible need to sleep or lapses into sleep, which may occur as sudden, irresistible sleep "attacks." Another common symptom of narcolepsy is cataplexy, which involves sudden muscle weakness caused by strong emotions such as laughter. The study was published in January 2014 issue of the journal SLEEP.

Related Links:

University of Lausanne


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
Silver Member
PCR Plates
Diamond Shell PCR Plates

Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more